Takeaway
- Intraprostatic injection of botulinum toxin-A (Botox; BTX‐A) significantly improves lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).
Why this matters
- Intraprostatic BTX‐A injection is a minimally invasive, nonsurgical BPH treatment alternative.
Study design
- Researchers studied patients with LUTS secondary to BPH who were treated with BTX-A injection after failing previous medical treatment or refusing surgical intervention (n=45; mean age, 64.4±6.6 years).
- They measured relevant clinical characteristics at baseline and at 2, 4, 8, and 12 weeks after injection.
- Funding: None disclosed.
Key results
- Mean international prostate symptom score (IPSS) decreased from 24.06 to 18.75 at 2 weeks and reached 16.37 at 12 weeks (P<.001>
- Mean maximum urinary flow rate (Qmax) increased from 9.08 to 10.44 mL/s at 2 weeks and 11.44 mL/s at 12 weeks (P<.001>
- Mean postvoiding residual urine (PVR) decreased from 82.62 to 57.66 mL at 12 weeks (P<.001>
- Mean prostate volume decreased from 67.44 to 66.06 cc at 12 weeks (P<.001>
- Patients reported no significant complications requiring medical treatment.
Limitations
- The study had a small sample size and no placebo control group.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionalsLogin to
account
Don’t have an account? Get started